|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
37,470,000 |
Market
Cap: |
308.38(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.28 - $13.99 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Voyager Therapeutics is a gene therapy company focused on developing treatments and platform technologies. Co.'s team has developed a proprietary adeno-associated virus (AAV) capsid discovery platform called TRACER (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) to facilitate the selection of AAV capsids with blood brain barrier crossing and cell-specific transduction properties for particular therapeutic applications. The TRACER discovery platform is a functional RNA-based AAV capsid discovery platform that allows for rapid in vivo evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
4,872,988 |
Total Buy Value |
$0 |
$0 |
$0 |
$41,694,868 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
13,472 |
42,011 |
76,578 |
2,756,162 |
Total Sell Value |
$132,861 |
$344,745 |
$641,708 |
$21,052,273 |
Total People Sold |
2 |
4 |
4 |
9 |
Total Sell Transactions |
2 |
9 |
13 |
45 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ecor1 Capital, Llc |
10% Owner |
|
2023-01-11 |
4 |
S |
$8.50 |
$934,615 |
I/I |
(110,000) |
3,851,507 |
|
-55% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2023-01-10 |
4 |
S |
$8.05 |
$2,709,433 |
I/I |
(336,400) |
3,961,507 |
|
-66% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2023-01-09 |
4 |
S |
$7.67 |
$3,498,295 |
I/I |
(456,000) |
4,297,907 |
|
-75% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2023-01-06 |
4 |
S |
$6.41 |
$2,487 |
D/D |
(388) |
36,194 |
|
-73% |
|
Carter Todd Alfred |
Chief Scientific Officer |
|
2022-12-31 |
4 |
A |
$5.17 |
$2,006 |
D/D |
388 |
36,582 |
|
- |
|
Pfreundschuh Peter P. |
Chief Financial Officer |
|
2022-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
|
- |
|
Carter Todd Alfred |
Chief Scientific OfficerOffice |
|
2022-09-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
36,194 |
|
53% |
|
Tepper Robert I |
10% Owner |
|
2022-08-25 |
4 |
S |
$6.22 |
$1,244,000 |
D/D |
(200,000) |
5,428,933 |
|
-9% |
|
Tepper Robert I |
10% Owner |
|
2022-08-24 |
4 |
S |
$6.09 |
$913,329 |
D/D |
(149,972) |
5,628,933 |
|
-2% |
|
Tepper Robert I |
10% Owner |
|
2022-08-16 |
4 |
S |
$6.04 |
$775,874 |
D/D |
(128,456) |
5,778,905 |
|
9% |
|
Tepper Robert I |
10% Owner |
|
2022-08-15 |
4 |
S |
$6.04 |
$820,280 |
D/D |
(135,808) |
5,907,361 |
|
10% |
|
Tepper Robert I |
10% Owner |
|
2022-08-12 |
4 |
S |
$6.12 |
$2,129,803 |
D/D |
(348,007) |
6,043,169 |
|
8% |
|
Pierce Glenn |
Director |
|
2022-07-14 |
4 |
AS |
$6.70 |
$63,730 |
D/D |
(9,512) |
16,788 |
|
-16% |
|
Higgins Michael J |
Director |
|
2022-07-14 |
4 |
AS |
$6.70 |
$93,070 |
D/D |
(13,891) |
31,314 |
|
-16% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2022-06-23 |
4 |
B |
$5.66 |
$2,126,543 |
I/I |
376,000 |
4,753,907 |
1.5 |
-8% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2022-06-21 |
4 |
B |
$5.28 |
$535,504 |
I/I |
101,400 |
4,377,907 |
1.5 |
-2% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2022-04-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,276,507 |
|
-18% |
|
Swartz Robin |
Chief Operating Officer |
|
2022-04-04 |
4 |
AS |
$8.25 |
$12,598 |
D/D |
(1,527) |
52,060 |
|
-30% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2022-04-04 |
4 |
AS |
$8.25 |
$22,985 |
D/D |
(2,786) |
114,963 |
|
-30% |
|
Sandrock Alfred |
President and CEO |
|
2022-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
Burek Julie |
VP, Finance |
|
2022-03-21 |
4 |
AS |
$8.29 |
$21,972 |
D/D |
(2,649) |
52,458 |
|
-20% |
|
Swartz Robin |
Chief Operating Officer |
|
2022-03-21 |
4 |
AS |
$8.29 |
$36,604 |
D/D |
(4,413) |
53,587 |
|
-20% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2022-03-21 |
4 |
AS |
$8.29 |
$41,100 |
D/D |
(4,955) |
117,749 |
|
-20% |
|
Burek Julie |
VP, Finance |
|
2022-02-17 |
4 |
AS |
$3.55 |
$2,801 |
D/D |
(789) |
55,107 |
|
71% |
|
Hesslein Robert W. |
Senior VP & General Counsel |
|
2022-02-17 |
4 |
AS |
$3.55 |
$14,555 |
D/D |
(4,100) |
122,704 |
|
71% |
|
162 Records found
|
|
Page 3 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|